$4.5M Direct Offering Priced at $1.50 a Share, 6% Below Market
INMB sits 29% above its 52-week low of $1.09.
Summary
INmune Bio is raising $4.50 million in gross proceeds by selling 3,000,000 shares to a single healthcare-focused institutional investor, which works out to $1.50 a share — about 6% below the $1.41 market price reference used here, so the discount is modest rather than punitive. The deal also includes warrants on another 3,000,000 shares struck at $1.65, exercisable in six months and good for 5.5 years, so the investor gets meaningful upside leverage on top of the equity. The raise is small relative to the company's roughly $42 million market cap, but it lands against a balance sheet that already carried a going concern warning with cash down to $18.4M in the Q2 10-Q, so every dollar of runway counts. Proceeds go to working capital and general corporate purposes, with closing expected on or about October 29, 2026. The company is mid-stream on UK MHRA and EU EMA filings for Ebstrocel and a planned US BLA, so the cash buys time to reach those milestones rather than funding a new program.
At the time of this announcement, INMB was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.2M. The 52-week trading range was $1.09 to $2.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.